Cytokines

Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients

Retrieved on: 
Monday, February 15, 2021

Richard Marsden, CEO of Synairgen, said: We are delighted that our inhaled interferon beta formulation has been entered into this US Government-funded Phase II/III study and that dosing has now commenced.

Key Points: 
  • Richard Marsden, CEO of Synairgen, said: We are delighted that our inhaled interferon beta formulation has been entered into this US Government-funded Phase II/III study and that dosing has now commenced.
  • We look forward to tracking the progress of the ACTIV-2 trial alongside our other COVID-19 trials.
  • The adaptive nature of the ACTIV-2 trial allows for comparison of multiple interventions with a shared group of placebo recipients.
  • Synairgen is also running an international 610 patient Phase III trial, which is progressing well, assessing the efficacy of inhaled interferon beta in hospitalised patients with COVID-19.

Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients

Retrieved on: 
Monday, February 15, 2021

Richard Marsden, CEO of Synairgen, said: We are delighted that our inhaled interferon beta formulation has been entered into this US Government-funded Phase II/III study and that dosing has now commenced.

Key Points: 
  • Richard Marsden, CEO of Synairgen, said: We are delighted that our inhaled interferon beta formulation has been entered into this US Government-funded Phase II/III study and that dosing has now commenced.
  • We look forward to tracking the progress of the ACTIV-2 trial alongside our other COVID-19 trials.
  • The adaptive nature of the ACTIV-2 trial allows for comparison of multiple interventions with a shared group of placebo recipients.
  • Synairgen is also running an international 610 patient Phase III trial, which is progressing well, assessing the efficacy of inhaled interferon beta in hospitalised patients with COVID-19.

Insights on the Erythropoietin (EPO) Global Market to 2030 - Identify Growth Segments for Investment

Retrieved on: 
Thursday, February 11, 2021

This report provides strategists, marketers and senior management with the critical information they need to assess the global erythropoietin (epo) market.

Key Points: 
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global erythropoietin (epo) market.
  • The global erythropoietin (EPO) market is expected to decline from $1.01 billion in 2019 to $0.95 billion in 2020 at a compound annual growth rate (CAGR) of -6.27%.
  • It compares the erythropoietin (epo) market with other segments of the erythropoietin (epo) market by size and growth, historic and forecast.
  • The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars.

Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences

Retrieved on: 
Thursday, February 11, 2021

Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.

Key Points: 
  • Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.
  • Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
  • In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

Worldwide Industry for Erythropoietin to 2030 - Featuring Amgen, Roche and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 10, 2021

The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars.

Key Points: 
  • The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars.
  • Stringent regulations imposed on the production and sales of erythropoietin drugs are predicted to hinder the growth of the erythropoietin market over the forecast period.
  • The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the approaching years.
  • Global Erythropoietin (EPO) Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005506/en/

Global Biosimilar Interleukins Market Report 2020-2030: - Major Players are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech and Sunshine Guojian Pharmaceutical

Retrieved on: 
Friday, February 5, 2021

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Biosimilar Interleukins Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Biosimilar Interleukins Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Biosimilar Interleukins Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar interleukins market.
  • Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech and Sunshine Guojian Pharmaceutical.
  • The biosimilar interleukins market covered in this report is segmented by type into IL-17; IL-23; IL-1; IL-5; IL-6; others.

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity

Retrieved on: 
Monday, February 1, 2021

When scientists blocked the effects of HGF in ImmCelz treated animals, the therapeutic effects where significantly inhibited.

Key Points: 
  • When scientists blocked the effects of HGF in ImmCelz treated animals, the therapeutic effects where significantly inhibited.
  • The data suggests one of the molecular mechanisms of action of ImmCelz is mediated by production of this therapeutic molecule.
  • Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .

Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

Retrieved on: 
Monday, February 1, 2021

The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions.

Key Points: 
  • The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions.
  • This approval expands Biogens industry-leading portfolio of MS treatments, which also includes the subcutaneous (SC) administration of PLEGRIDY, and follows the European Commissions marketing authorization for the IM administration in December 2020.
  • A phase 1, open-label, crossover study to evaluate the bioequivalence of intramuscular and subcutaneous peginterferon beta-1a in healthy volunteers.
  • Poster presented at: Americas Committee for Treatment and Research in Multiple Sclerosis - 2020 Forum; 2020 Feb 27-29; West Palm Beach, Florida, USA.

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

Retrieved on: 
Wednesday, January 27, 2021

Humanigen is actively enrolling patients in a Phase 3 study in the U.S. and Brazil and preparing for a potential COVID-19 Emergency Use Authorization (EUA) for lenzilumab.

Key Points: 
  • Humanigen is actively enrolling patients in a Phase 3 study in the U.S. and Brazil and preparing for a potential COVID-19 Emergency Use Authorization (EUA) for lenzilumab.
  • We are very pleased to be working with Aji Bio-Pharma for the fill finish production of lenzilumab, said Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen.
  • Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients needs.
  • Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.

BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases

Retrieved on: 
Tuesday, January 26, 2021

The testing was conducted at -20C and +2C to +8C temperatures which correspond toordinary freezer and refrigerator temperatures.

Key Points: 
  • The testing was conducted at -20C and +2C to +8C temperatures which correspond toordinary freezer and refrigerator temperatures.
  • The interferon met all established stability testing criteria.
  • The ability to ship, storeand use the product at these temperatures greatly simplifies the distribution chain and patient use protocols.
  • Neva Analytics is registered with the FDA and provides services to pharmaceutical anddevice manufacturers from pre-clinical to commercial stage.